RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness

Osteosarcoma is a malignant tumor of bone characterized by its high metastatic potential. For the development of metastasis, activation of matrix metalloproteinases (MMPs) is required. A novel MMPs inhibitor, reversion inducing cysteine rich protein with Kazal motifs (RECK), is known to down‐regulate MMPs and suppress the invasive and metastatic potential in many tumor‐derived cell lines and some types of tumors. The expression of RECK and its role in tumor invasiveness have never been studied in osteosarcoma. We examined RECK mRNA expression and MMPs activation in osteosarcoma using quantitative real time PCR, gelatin zymography, invasion assay, and transfection experiments. RECK was expressed but down‐regulated in osteosarcoma cells. Activation of pro‐MMP‐2 was observed in all samples, whereas activation of MMP‐2 and pro‐MMP‐9 was detected in only 11% and 7% of the samples, respectively. MMP‐9 was not activated in any of the samples. The level of RECK expression was inversely correlated with pro‐MMP‐2 activation, and overexpression of RECK by transfection resulted in decreased pro‐MMP‐2 activation and reduced tumor invasiveness. These findings suggest that RECK plays an important role in the invasiveness of osteosarcoma. © 2007 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 25:696–702, 2007

[1]  S. Arii,et al.  RECK gene expression in hepatocellular carcinoma: Correlation with invasion‐related clinicopathological factors and its clinical significance , 2001, Hepatology.

[2]  M. Hidalgo,et al.  Development of matrix metalloproteinase inhibitors in cancer therapy. , 2001, Journal of the National Cancer Institute.

[3]  K. Tryggvason,et al.  Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. , 1993, The American journal of pathology.

[4]  K. Danø,et al.  Stromal cell expression of components of matrix-degrading protease systems in human cancer. , 1996, Enzyme & protein.

[5]  V. Weaver.  Membrane-associated MMP regulators: novel cell adhesion tumor suppressor proteins? , 2002, Developmental cell.

[6]  M. Gebhardt,et al.  Biology and therapeutic advances for pediatric osteosarcoma. , 2004, The oncologist.

[7]  David B. Alexander,et al.  The Membrane-Anchored MMP Inhibitor RECK Is a Key Regulator of Extracellular Matrix Integrity and Angiogenesis , 2001, Cell.

[8]  K. Livak,et al.  Real time quantitative PCR. , 1996, Genome research.

[9]  J. Verweij,et al.  Matrix metalloproteinase inhibitors: current developments and future perspectives. , 2001, The Oncologist.

[10]  P. Picci,et al.  Role of MMP-9 and its tissue inhibitor TIMP-1 in human osteosarcomaFindings in 42 patients followed for 1–16 years , 2004, Acta orthopaedica Scandinavica.

[11]  O. Fodstad,et al.  Matrix metalloproteinases participate in osteosarcoma invasion. , 2005, The Journal of surgical research.

[12]  A. Albini,et al.  Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. , 1998, Pathology oncology research : POR.

[13]  P. Choong.  The molecular basis of skeletal metastases. , 2003, Clinical orthopaedics and related research.

[14]  R. Grimer,et al.  Stage-IIB osteosarcomas around the knee. A study of MMP-9 in surviving tumour cells. , 2002, The Journal of bone and joint surgery. British volume.

[15]  Y Ikawa,et al.  Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P. Span,et al.  Matrix metalloproteinase inhibitor reversion‐inducing cysteine‐rich protein with Kazal motifs , 2003, Cancer.

[17]  Ralf J Kohal,et al.  A systematic review of the influence of different titanium surfaces on proliferation, differentiation and protein synthesis of osteoblast-like MG63 cells. , 2004, Clinical oral implants research.

[18]  M. Imamura,et al.  RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.